Sensus Healthcare (NASDAQ:SRTS) Director Acquires $112,765.25 in Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta acquired 34,697 shares of the stock in a transaction dated Monday, August 24th. The shares were bought at an average cost of $3.25 per share, for a total transaction of $112,765.25. Following the completion of the transaction, the director owned 209,310 shares in the company, valued at approximately $680,257.50. This represents a 19.87% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website.

Sensus Healthcare Trading Up 2.4%

Shares of NASDAQ:SRTS opened at $3.37 on Friday. Sensus Healthcare, Inc. has a 12-month low of $2.66 and a 12-month high of $5.49. The company has a market cap of $55.47 million, a PE ratio of -3.59 and a beta of 1.10. The stock has a 50 day moving average of $3.04 and a 200 day moving average of $3.52.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.41). The firm had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $4.60 million. Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%.

Hedge Funds Weigh In On Sensus Healthcare

Several hedge funds have recently modified their holdings of SRTS. EP Wealth Advisors LLC bought a new position in shares of Sensus Healthcare during the second quarter worth $49,000. XTX Topco Ltd purchased a new stake in Sensus Healthcare in the 4th quarter worth $77,000. Jane Street Group LLC purchased a new stake in Sensus Healthcare in the 4th quarter worth $79,000. Ingalls & Snyder LLC purchased a new stake in Sensus Healthcare in the 4th quarter worth $219,000. Finally, BlackRock Inc. bought a new position in shares of Sensus Healthcare during the 2nd quarter valued at about $252,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Weiss Ratings cut shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Citigroup reiterated a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Wall Street Zen cut Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Lake Street Capital lowered their price objective on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Finally, Alliance Global Partners reaffirmed a “buy” rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $5.83.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.